Evotec and PsychoGenics have formed a strategic alliance to provide integrated CNS drug discovery solutions to the pharma and biotech industries. The partners will provide clients with access to both firms’ complementary drug discovery platforms for the identification and development of new CNS therapeutics.
PsychoGenics specializes in preclinical neurobiology and the provision of CNS drug discovery solutions including a broad range of target screening, discovery, and validation resources. The firm’s expertise is based on its high-throughput behavioral testing platforms, which combine expertise in behavioral neurobiology with the power of bioinformatics.
Evotec offers stand-alone and integrated drug discovery solutions covering all activities from target to clinic. The firm has specialist expertise in therapeutic fields including neuroscience, pain, metabolic diseases, as well as oncology and inflammation.